The efficacy and safety of alpha-1-adrenergic blocker alfuprost MP (alfuzosin) at a dose of 10 mg once a day and a fifth-type phosphodiesterase inhibitor viatile (sildenafil) 50 mg once a day in the combined treatment of 75 patients with benign prostate hyperplasia (BPH) with low urinary tract symptoms and erectile dysfunction (ED). Patients were divided into 3 groups, depending on the severity of ED and urination disorders. The 1st (main) group included 34 (45.3%) patients with moderate-stage ED (IIEF 11-15 points, IPSS 10-12 points) who got a combination therapy that included the intake of viatile (sildenafil) 50 mg in day daily and alfuprost MP (alfuzosin) 10 mg once a day for 12 weeks. The second group included 21 (28%) patients with a mild degree of ED (IIEF 16-20 points, IPSS-10-12 points), who received only viatile (sildenafil) 50 mg daily once a day with the same duration. The third group included 20 (26.6%) patients with mild ED (IIEF 16-20, IPSS 7-8), who received only alfuprost MP (alfuzosin) 10 mg once a day for 12 weeks. After the end of treatment 29 (85.3%) patients of the 1st group, 16 (76.2%) patients of the 2nd group and 11 (55%) patients of the 3rd group noted high efficiency. The patients of the 1st group had the greatest clinical effect of treatment - an increase in the quality of erection by an average of 7.0 according to IIEF, an increase in blood flow in the vessels of the penis by 3.5 times, decrease in the IPSS index by 5 points, and an increase in the rate of urination. The results of the study indicate the advisability of prescribing patients with BPH with low unitary tract symptoms and erectile dysfunction of combined therapy with alpha-blockers and phosphodiesterase type 5 inhibitors. (For citation: Kalinina SN, Burlaka OO, Aleksandrov MS, Vydryn PS. Diagnosis and treatment of lower urinary tract symptoms and erectile dysfunction in patients with benign prostate hyperplasia. Urologicheskie vedomosti. 2018;8(1):26-33. doi: 10.17816/uroved8126-33).
Correlation between Fasting Glucose, Erectile Dysfunction, and Lower Urinary Tract Symptoms in Benign Prostate Hyperplasia Patients
